EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression

Kohei Yamada, Tomokazu Tanaka, Keita Kai iD, Shohei Matsufuji, Kotaro Ito, Yoshihiko Kitajima, Tatsuya Manabe, Hirokazu Noshiro

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241411546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Kohei Yamada und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease, Liver Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory processes play major roles in carcinogenesis and the progression of hepatocellular carcinoma (HCC) derived from non-alcoholic steatohepatitis (NASH). But, there are no therapies for NASH-related HCC, especially focusing on these critical steps. Previous studies have reported that farnesyltransferase inhibitors (FTIs) have anti-inflammatory and anti-tumor effects. However, the influence of FTIs on NASH-related HCC has not been elucidated. In hepatoblastoma and HCC cell lines, HepG2, Hep3B, and Huh-7, we confirmed the expression of hypoxia-inducible factor (HIF)-1α, an accelerator of tumor aggressiveness and the inflammatory response. We established NASH-related HCC models under inflammation and free fatty acid burden and confirmed that HIF-1α expression was increased under both conditions. Tipifarnib, which is an FTI, strongly suppressed increased HIF-1α, inhibited cell proliferation, and induced apoptosis. Simultaneously, intracellular interleukin-6 as an inflammation marker was increased under both conditions and significantly suppressed by tipifarnib. Additionally, tipifarnib suppressed the expression of phosphorylated nuclear factor-κB and transforming growth factor-β. Finally, in a NASH-related HCC mouse model burdened with diethylnitrosamine and a high-fat diet, tipifarnib significantly reduced tumor nodule formation in association with decreased serum interleukin-6. In conclusion, tipifarnib has anti-tumor and anti-inflammatory effects in a NASH-related HCC model and may be a promising new agent to treat this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularNon-alcoholic Fatty Liver DiseaseLiver NeoplasmsMiceAnimalsFarnesyltranstransferaseInterleukin-6Hypoxia-Inducible Factor 1, alpha SubunitEnzyme InhibitorsAnti-Inflammatory AgentsInflammationCell Line, Tumor

Stichwörter der Autor:innen

Warburg effectanti-inflammatory responsefarnesyltransferase inhibitorhepatocellular carcinomahypoxia-inducible factor-1αinterleukin-6non-alcoholic steatohepatitisnuclear factor-κBreactive oxygen speciestransforming growth factor-β

Substanzen

FarnesyltranstransferaseInterleukin-6Hypoxia-Inducible Factor 1, alpha SubunitEnzyme InhibitorsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan.
  • Department of Pathology, Saga University Faculty of Medicine, Saga 849-8501, Japan.
  • Department of Surgery, National Hospital Organization Higashisaga Hospital, Saga 849-0101, Japan.

ORCID-Profile: Keita Kai

Förderung

  • Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Scientific Research

Zitieren

APA

Yamada, K., Tanaka, T., Kai, K., Matsufuji, S., Ito, K., Kitajima, Y., Manabe, T., & Noshiro, H. (2023). Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241411546

Vancouver

Yamada K, Tanaka T, Kai K, Matsufuji S, Ito K, Kitajima Y, et al. Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241411546

BibTeX
@article{Yamada2023,
  author = {Yamada, Kohei and Tanaka, Tomokazu and Kai, Keita and Matsufuji, Shohei and Ito, Kotaro and Kitajima, Yoshihiko and Manabe, Tatsuya and Noshiro, Hirokazu},
  title = {Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241411546}
}
Kostenlos starten →